Post Marketing Surveillance (PMS) of JARDIANCE in Chronic Heart Failure (CHF)
NCT05262764 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1200
Last updated 2026-03-24
Summary
Study objective is to investigate the safety and effectiveness of long-term daily use of JARDIANCE® Tablets in patients with chronic heart failure (CHF) under real-world use.
Conditions
Interventions
- DRUG
-
Treatment was in accordance with the latest guidelines from The Japanese Circulation Society (JCS).
Sponsors & Collaborators
- collaborator INDUSTRY
- lead INDUSTRY
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-04-15
- Primary Completion
- 2024-06-21
- Completion
- 2024-06-28
Countries
- Japan
Study Locations
More Related Trials
-
Investigation of Biomarker Response to SGLT2 Inhibition in Heart Failure
NCT06140251 ·Status: RECRUITING
-
Dapagliflozin Therapy In Cardiac Surgery
NCT05621551 ·Status: COMPLETED ·Phase: PHASE4
-
A Bioequivalence Study of Two Formulations of 10-mg Empagliflozin Tablets in Healthy Thai Volunteers Under Fasting Conditions
NCT06308679 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
The Efficacy and Safety of Dapagliflozin in Improving Heart Failure in Dialysis Patients
NCT06365541 ·Status: RECRUITING ·Phase: PHASE4
-
Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease
NCT06260059 ·Status: RECRUITING ·Phase: PHASE4
-
Bioequivalence Study of Empagliflozin Tablet in Healthy Participants.
NCT03771781 ·Status: COMPLETED ·Phase: NA
-
Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure
NCT05392764 ·Status: RECRUITING ·Phase: PHASE3
-
Effect of Empagliflozin 10 vs 25 mg on LV Remodeling in Diabetic Patients With Anterior STEMI With Reduced LVEF
NCT07169981 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase I PK Study of Balcinrenone/Dapagliflozin in Healthy Chinese Participants
NCT06651021 ·Status: COMPLETED ·Phase: PHASE1
-
Effects of Dapagliflozin on Inflammatory Factorslevel and Prognosis in Type 2 Diabetes With Acute Myocardial Infarction
NCT05050500 ·Status: COMPLETED ·Phase: PHASE4
-
Effects of Canagliflozin on Intravascular Volume and Hemodynamics
NCT03190798 ·Status: WITHDRAWN ·Phase: PHASE4
-
Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome
NCT07273838 ·Status: RECRUITING ·Phase: PHASE2
-
SGLT-2 Inhibitor Effects on Cardiac and Hepatic Metabolic Profiles for the Diabetes Patients Combined With Obesity
NCT05764811 ·Status: COMPLETED ·Phase: NA
-
JARDIANCE Regulartory Post Marketing Surveillance in Korean Type 2 Diabetes Mellitus
NCT02848833 ·Status: COMPLETED
-
A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease
NCT06610526 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension
NCT01031680 ·Status: COMPLETED ·Phase: PHASE3
-
A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
NCT03152552 ·Status: TERMINATED ·Phase: PHASE2
-
A Study on Impact of Canagliflozin on Health Status, Quality of Life, and Functional Status in Heart Failure
NCT04252287 ·Status: COMPLETED ·Phase: PHASE3
-
Effects Of Sodium Glucose Cotranspoter 2 Inhibitors On Heart And Kidneys In Fabry Disease Patients
NCT05710367 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study to Investigate the Mechanistic Effects of Dapagliflozin Alone or in Combination With Balcinrenone, Compared to Balcinrenone and Placebo on Body Fluid and Electrolyte Handling and Energy Metabolism in Participants Over 50 Years of Age With Chronic Kidney Disease.
NCT05884866 ·Status: COMPLETED ·Phase: PHASE2
-
SGLT2 Inhibitors and Treatment of Heart Failure in Severe Renal Insufficiency
NCT05737186 ·Status: TERMINATED ·Phase: PHASE4
-
Effect of Dapagliflozin on the Progression From Prediabetes to T2DM in Subjects With Myocardial Infarction
NCT03658031 ·Status: UNKNOWN ·Phase: PHASE3
-
Implementation of SGLT-2 Inhibitors in Patients With Heart Failure Through a New Digital Strategy
NCT05890131 ·Status: COMPLETED ·Phase: NA
-
Dapagliflozin for Cardio-renal Protection After ICU Discharge
NCT07025629 ·Status: RECRUITING ·Phase: PHASE3
-
A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease
NCT03036150 ·Status: COMPLETED ·Phase: PHASE3